Literature DB >> 22866151

Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent.

Tomoya Fukui1, Hisashi Mitsufuji, Masaru Kubota, Hidenori Inaoka, Minoru Hirose, Keiichi Iwabuchi, Noriyuki Masuda, Hirosuke Kobayashi.   

Abstract

Topoisomerase I (TOP-I) mutations have been shown to be correlated to irinotecan resistance in vitro. However, the prevalence of TOP-I germline mutations has yet to be systematically elucidated. On the other hand, polymorphisms of UGT1A1 have been shown to be associated with CPT-11 toxicity in clinical situations. The primary aim of this study was to investigate the prevalence of mutations in the TOP-I exons associated with CPT-11 resistance, including untreated cancer tissue. A secondary aim was to confirm the less frequent UGT1A1*28 and more frequent UGT1A1*6 in individuals of Asian descent compared to Caucasians and individuals of African descent. The prevalence of 5 reported TOP-I mutations in exons was investigated in volunteers (n=236) using DNA sequencing of the PCR products. The prevalence of TOP-I mutations in untreated lung cancer tissues (n=16) was also investigated. Additionally, 3 UGT1A1 polymorphisms, UGT1A1*6, *27 and *28, were investigated in volunteers (n=126). There were no mutations of TOP-I in any of the 236 subjects or in the untreated lung tissues. Among 128 subjects, the distribution of homozygous polymorphisms of UGT1A1 was: UGT1A1*28 in 3 (2.4%) and UGT1A1*6 in 4 (3.2%) subjects, and co-occurrence of heterozygous polymorphisms for both UGT1A1*6 and UGT1A1*28 in 4 (3.2%) subjects, and for UGT1A1*27 and UGT1A1*28 in 1 subject (0.8%). The Hardy-Weinberg deviation test showed there was no significant deviation from the equilibrium, and the association analysis indicated no significant linkage between UGT1A1*6 and UGT1A1*28. In conclusion, TOP-I genetic mutations correlated to CPT-11 resistance were not detected in any of the subjects and untreated lung cancer tissues. Less frequent UGT1A1*28 and more frequent UGT1A1*6 were confirmed in East Asian individuals compared to Caucasians and individuals of African descent. Linkage disequilibrium was not detected between UGT1A1*6 and UGT1A1*28.

Entities:  

Year:  2011        PMID: 22866151      PMCID: PMC3408035          DOI: 10.3892/ol.2011.346

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

1.  Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.

Authors:  Junji Tsurutani; Takashi Nitta; Tomonori Hirashima; Takefumi Komiya; Hisao Uejima; Hirohito Tada; Negoro Syunichi; Aritomo Tohda; Masahiro Fukuoka; Kazuhiko Nakagawa
Journal:  Lung Cancer       Date:  2002-03       Impact factor: 5.705

Review 2.  An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore.

Authors:  Balram Chowbay; Shufeng Zhou; Edmund J D Lee
Journal:  Drug Metab Rev       Date:  2005       Impact factor: 4.518

Review 3.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Authors:  R H Mathijssen; R J van Alphen; J Verweij; W J Loos; K Nooter; G Stoter; A Sparreboom
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

4.  Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.

Authors:  Gary S Laco; Jack R Collins; Brian T Luke; Heiko Kroth; Jane M Sayer; Donald M Jerina; Yves Pommier
Journal:  Biochemistry       Date:  2002-02-05       Impact factor: 3.162

5.  UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females.

Authors:  J Mercke Odeberg; J Andrade; K Holmberg; P Hoglund; U Malmqvist; J Odeberg
Journal:  Eur J Clin Pharmacol       Date:  2006-08-15       Impact factor: 2.953

6.  Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.

Authors:  Jackie Yao Liu; Kevin Qu; Anthony D Sferruzza; Richard A Bender
Journal:  Anticancer Drugs       Date:  2007-07       Impact factor: 2.248

7.  Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American.

Authors:  Nahoko Kaniwa; Kouichi Kurose; Hideto Jinno; Toshiko Tanaka-Kagawa; Yoshiro Saito; Mayumi Saeki; Jun-Ichi Sawada; Masahiro Tohkin; Ryuichi Hasegawa
Journal:  Drug Metab Dispos       Date:  2004-11-30       Impact factor: 3.922

8.  Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

Authors:  Janelle M Hoskins; Eugenio Marcuello; Albert Altes; Sharon Marsh; Taylor Maxwell; Derek J Van Booven; Laia Paré; Robert Culverhouse; Howard L McLeod; Montserrat Baiget
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

9.  Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.

Authors:  Jang-Yang Chang; Jin-Fen Liu; Shin-Hun Juang; Tsang-Wu Liu; Li-Tzong Chen
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

10.  Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines.

Authors:  F Moisan; M Longy; J Robert; V Le Morvan
Journal:  Br J Cancer       Date:  2006-09-19       Impact factor: 7.640

View more
  7 in total

1.  Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.

Authors:  Xun Cai; Chuan Tian; Liwei Wang; Rongyuan Zhuang; Xiaowei Zhang; Yuanbiao Guo; Hongmin Lu; Hui Wang; Xiaoyu Li; Junwei Gao; Qi Li; Chungang Wang
Journal:  Cancer Biol Ther       Date:  2017-02-17       Impact factor: 4.742

2.  Obstetric Obesity is Associated with Neonatal Hyperbilirubinemia with High Prevalence in Native Hawaiians and Pacific Island Women.

Authors:  Luc Ra Rougée; Shogo J Miyagi; Abby C Collier
Journal:  Hawaii J Med Public Health       Date:  2016-12

3.  Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.

Authors:  Yutaka Negoro; Ryoichi Yano; Mari Yoshimura; Yoko Suehiro; Shinji Yamashita; Takaaki Kodawara; Kyohei Watanabe; Hitoshi Tsukamoto; Toshiaki Nakamura; Maiko Kadowaki; Miwa Morikawa; Yukihiro Umeda; Masaki Anzai; Tamotsu Ishizuka; Nobuyuki Goto
Journal:  Int J Clin Oncol       Date:  2018-10-17       Impact factor: 3.402

4.  Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.

Authors:  Chalirmporn Atasilp; Mohitosh Biswas; Pimonpan Jinda; Nutthan Nuntharadthanaphong; Jiratha Rachanakul; Yaowaluck Hongkaew; Natchaya Vanwong; Surasak Saokaew; Chonlaphat Sukasem
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

5.  Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients.

Authors:  Naoki Horikawa; Tsukasa Baba; Noriomi Matsumura; Ryusuke Murakami; Kaoru Abiko; Junzo Hamanishi; Ken Yamaguchi; Masafumi Koshiyama; Yumiko Yoshioka; Ikuo Konishi
Journal:  BMC Cancer       Date:  2015-10-19       Impact factor: 4.430

Review 6.  Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review.

Authors:  Shogo Ozawa; Toshitaka Miura; Jun Terashima; Wataru Habano
Journal:  Cancer Drug Resist       Date:  2021-11-02

7.  Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor.

Authors:  Qian Li; Tao Sun; Hua Zhang; Wei Liu; Yu Xiao; Hongqi Sun; Wencheng Yin; Yanhong Yao; Yangchun Gu; Yan'e Liu; Fumei Yi; Qiqi Wang; Jinyu Yu; Baoshan Cao; Li Liang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.